Kevin P Currie, 40117 Leeward Ln, Port Jefferson, NY 11777

6414147, Jul 2, 2002

Dec 22, 1999

09/470940

Kevin S. Currie - North Branford CT
Pamela Albaugh - Clinton CT
Paul Chen - Thousand Oaks CA

Neurogen Corporation - Branford CT

C07D47318

544276

Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein: W is oxygen or sulfur; X is (un)substituted lower alkyl; or X is (un)substituted aryl or heteroaryl; Y is hydrogen or lower alkyl; Z is lower alkenyl, lower alkynyl, or (un)substituted lower alkyl; T is (un)substituted aryl or heteroaryl. The compounds are highly selective agonists, antagonists, or inverse agonists for GABAa brain receptors, or prodrugs of agonists, antagonists, or inverse agonists for GABAa brain receptors. Thus these compounds are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, Downs Syndrome, overdose with benzodiazepine drugs, and for the enhancement of memory.

6777422, Aug 17, 2004

Mar 27, 2003

10/401135

Kyungae Lee - Guilford CT
Scott Mitchell - East Haven CT
Robert Ohliger - Madison CT
Lu Yan Zhang - Branford CT
He Zhao - Branford CT
Kevin Currie - North Branford CT

Neurogen Corp. - Branford CT

C07D21700

514278, 546 15, 546144, 546146, 514307

Substituted tetrahydroisoquinolines and related compounds are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological C5a receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

6916819, Jul 12, 2005

Dec 21, 2001

10/038069

Guiying Li - Branford CT, US
John M. Peterson - Madison CT, US
Pamela Albaugh - Carmel IN, US
Kevin S. Currie - North Branford CT, US
Guolin Cai - Thousand Oaks CA, US
Linda M. Gustavson - Guilford CT, US
Kyungae Lee - Guilford CT, US
Alan Hutchison - Madison CT, US
Vinod Singh - Kanpur, IN
George D. Maynard - Clinton CT, US
Jun Yuan - Guilford CT, US
Ling Hong Xie - Guilford CT, US
Manuka Ghosh - Branford CT, US
Nian Liu - North Branford CT, US

Neurogen Corporation - Branford CT

C07D403/12
C07D403/14
C07D401/14
A61K031/4184
A61P025/24

514256, 514372, 514374, 514378, 514394, 514395, 514339, 514307, 544333, 206570, 546144, 546167, 5462697, 5462714, 5462724, 5462734, 5462737, 548181, 548206, 548235, 548247, 548254, 548255, 5483047, 5483061

This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAreceptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAreceptors in tissue sections.

6916827, Jul 12, 2005

May 15, 2003

10/438496

George D. Maynard - Clinton CT, US
Jun Yuan - Guilford CT, US
George P. Luke - Clinton CT, US
Kevin Currie - North Branford CT, US

Neurogen Corporation - Branford CT

A61K031/437
A61K031/4184
A61K031/506
C07D471/04
C07D403/06

514303, 514256, 514393, 514394, 544333, 546118, 5483027, 5483061

Substituted ring-fused imidazole derivatives that bind to GABAreceptors are provided. Such compounds may be used to modulate ligand binding to GABAreceptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAreceptors (e. g. , receptor localization studies).

6916830, Jul 12, 2005

Apr 15, 2004

10/824826

Kyungae Lee - Guilford CT, US
Scott A. Mitchell - East Haven CT, US
Robert Ohliger - Madison CT, US
LuYan Zhang - Branford CT, US
He Zhao - Branford CT, US
Kevin S. Currie - North Branford CT, US

Neurogen Corporation - Branford CT

C07D211/68
A61K031/44

514317, 514357, 546192, 546336

Substituted tetrahydroisoquinolines and related compounds are provided. Such compounds are ligands that may be used to modulate C5a receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological C5a receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies:.

6919340, Jul 19, 2005

Apr 21, 2003

10/419682

Kevin S. Currie - North Branford CT, US
Robert W. DeSimone - Durham CT, US
Douglas A. Pippin - Branford CT, US
James W. Darrow - Wallingford CT, US
Scott A. Mitchell - East Haven CT, US

Cellular Genomics, Inc. - Branford CT

A01N043/58
A01N043/60
A61K031/495
A61K031/50
C07D471/00

514249, 544350

A novel composition comprises a compound of Formula 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.

7160885, Jan 9, 2007

Feb 10, 2004

10/776631

Kevin S. Currie - North Branford CT, US
Robert W. DeSimone - Durham CT, US
Douglas A. Pippin - Branford CT, US
James W. Darrow - Wallingford CT, US
Scott A. Mitchell - East Haven CT, US

CGI Pharmaceuticals, Inc. - Branford CT

A01N 43/58
A01N 43/60
A61K 31/50
A61K 31/495
C07D 471/00

514249, 544350

This invention pertains to compounds of Formula I:The variables R, R, R, Z, Z, W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and neurodegenerative diseases. Thus methods of treatment include administering a sufficient amount of a compound of Formula I or form thereof to decrease the symptoms or slow the progression of these diseases or disorders. The invention also encompasses methods of treating non-human patients, including livestock and domesticated companion animals, suffering from a disease or disorder responsive to Hsp90 complex modulation.

7189723, Mar 13, 2007

Feb 10, 2004

10/776002

Scott A. Mitchell - East Haven CT, US
Kevin S. Currie - North Branford CT, US
Robert W. DeSimone - Durham CT, US
Douglas A. Pippin - Branford CT, US

CGI Pharmaceuticals, Inc. - Branford CT

A01N 43/58
A01N 43/60
A61K 31/50
A61K 31/495
C07D 47/00

514249, 544350

This invention pertains to compounds of Formula I:The variables R, R, R, Z, Z, W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to EphBkinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including of breast neoplasma, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Thus methods of treatment include administering a sufficient amount of a compound or salt of the invention to decrease the symptoms or slow the progression of these diseases or disorders. The invention also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an disease or disorder responsive to EphB modulation.